Davenport & Co’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-113,670
| Closed | -$70K | – | 780 |
|
|
2019
Q3 | $70K | Sell |
113,670
-1,200
| -1% | -$669 | ﹤0.01% | 673 |
|
|
2019
Q2 | $71K | Hold |
114,870
| – | – | ﹤0.01% | 674 |
|
|
2019
Q1 | $127K | Hold |
114,870
| – | – | ﹤0.01% | 638 |
|
|
2018
Q4 | $52K | Sell |
114,870
-5,000
| -4% | -$4.56K | ﹤0.01% | 624 |
|
|
2018
Q3 | $192K | Hold |
119,870
| – | – | ﹤0.01% | 651 |
|
|
2018
Q2 | $43K | Hold |
119,870
| – | – | ﹤0.01% | 688 |
|
|
2018
Q1 | $34.8K | Hold |
119,870
| – | – | ﹤0.01% | 683 |
|
|
2017
Q4 | $116K | Buy |
119,870
+2,124
| +2% | +$2.44K | ﹤0.01% | 673 |
|
|
2017
Q3 | $178K | Hold |
117,746
| – | – | ﹤0.01% | 636 |
|
|
2017
Q2 | $146K | Buy |
117,746
+10,726
| +10% | +$12.3K | ﹤0.01% | 635 |
|
|
2017
Q1 | $110K | Hold |
107,020
| – | – | ﹤0.01% | 611 |
|
|
2016
Q4 | $110K | Buy |
107,020
+7,920
| +8% | +$8.9K | ﹤0.01% | 611 |
|
|
2016
Q3 | $103K | Sell |
99,100
-2,000
| -2% | -$2.42K | ﹤0.01% | 600 |
|
|
2016
Q2 | $148K | Buy |
101,100
+2,000
| +2% | +$2.58K | ﹤0.01% | 565 |
|
|
2016
Q1 | $115K | Buy |
99,100
+2,500
| +3% | +$3.35K | ﹤0.01% | 561 |
|
|
2015
Q4 | $116K | Sell |
96,600
-2,000
| -2% | -$2.66K | ﹤0.01% | 563 |
|
|
2015
Q3 | $159K | Hold |
98,600
| – | – | ﹤0.01% | 543 |
|
|
2015
Q2 | $205K | Hold |
98,600
| – | – | ﹤0.01% | 540 |
|
|
2015
Q1 | $293K | Buy |
98,600
+5,400
| +6% | +$17.1K | ﹤0.01% | 487 |
|
|
2014
Q4 | $294K | Hold |
93,200
| – | – | ﹤0.01% | 468 |
|
|
2014
Q3 | $316K | Buy |
93,200
+22,200
| +31% | +$64.7K | 0.01% | 441 |
|
|
2014
Q2 | $185K | Buy |
71,000
+6,000
| +9% | +$16.6K | ﹤0.01% | 555 |
|
|
2014
Q1 | $183K | Buy |
65,000
+5,000
| +8% | +$15.1K | ﹤0.01% | 543 |
|
|
2013
Q4 | $164K | Buy |
+60,000
| New | +$168K | ﹤0.01% | 536 |
|
Davenport & Co's CELGZ Position: Q4 2019 in Review
Davenport & Co sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2019, closing a stake of 113,670 shares — an estimated $70K sold.
Davenport & Co first reported a position in CELGZ in Q4 2013 and held it in 24 quarters. The position peaked at $316K in Q3 2014. 0 funds tracked by Wall St. Rank hold CELGZ as of Q4 2019.
- Davenport & Co reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
- Davenport & Co sold 113,670 Celgene Corporation Contingent Value Rights shares in Q4 2019, an estimated $70K.
- Davenport & Co first reported a position in Celgene Corporation Contingent Value Rights in Q4 2013 and held it in 24 quarters.
- Davenport & Co's Celgene Corporation Contingent Value Rights position peaked at $316K in Q3 2014.
- 0 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2019.
Based on Davenport & Co's 13F filing for Q4 2019, filed 22 Jan 2020.